Shpuld a teenager transition gender identity medical transition?
There is no single agreed answer. Canadian and US medical bodies generally support offering medical transition to carefully assessed teens, while a major UK-commissioned review found the evidence too weak to justify routine use of puberty blockers.
The decision usually depends on an individual assessment by a specialist team, weighing an individual teen's history, mental health, and family situation rather than a blanket rule.
Mixed
Guideline bodies disagree: Canadian and US groups recommend affirming care after assessment, but the UK's Cass Review and a 2025 systematic review/meta-analysis found only very-low-certainty evidence from observational and before-after studies, not randomized trials.
What the evidence says
This is one of the most debated questions in teen health right now, and different countries have reached different conclusions. There isn't one clear "yes" or "no" answer that all doctors agree on.
In Canada, the Canadian Paediatric Society says gender-affirming hormone therapy can be offered to teens who have a confirmed diagnosis of gender dysphoria, understand the risks and benefits, and are otherwise mentally stable enough to start treatment. They note this approach has been linked to better wellbeing and lower reported suicidal thoughts in some studies, though they also say it carries some health risks that need to be discussed with a doctor. The US Endocrine Society and WPATH (an international group) take a similar approach, generally suggesting hormones can start around age 16, sometimes earlier for individual reasons.
However, the United Kingdom looked at this question very closely through an independent project called the Cass Review, which included a detailed look at all the research. It concluded the evidence was too weak and uncertain to justify using puberty blockers routinely, and puberty blockers are now restricted for under-18s with gender dysphoria in the UK. A recent systematic review done by Canadian researchers at McMaster University reached a similar conclusion: the studies done so far are mostly small, don't compare treated and untreated groups well, and leave real uncertainty about how puberty blockers affect mood, body development, and gender dysphoria itself over time.
Part of the disagreement comes down to the type of evidence available. Almost none of the research is from gold-standard studies where teens are randomly assigned to treatment or no treatment. Most is from following groups of teens who chose treatment and watching what happened, which can't rule out other explanations for improvement.
Because there's no medical emergency and views differ this much, this is a decision best made slowly, with a team that includes a doctor experienced in gender care and a mental health professional, looking at your teen's whole situation rather than following one country's rule alone. Social transition, things like a new name, pronouns, or clothing, is a separate and reversible step from medical transition, and many teens explore that first.
Sources
-
Guideline
An affirming approach to caring for transgender and gender-diverse youth
Canadian Paediatric Society
Canadian guideline supporting individualized affirming care with informed consent
-
Guideline
Children and young people's gender services: implementing the Cass Review recommendations
NHS England
UK policy restricting puberty blockers under 18 due to limited evidence
-
Systematic review
Puberty blockers for gender dysphoria in youth: A systematic review and meta-analysis
Archives of Disease in Childhood (PubMed)
Found very low certainty evidence; McMaster University research team
-
Guideline
Proposed changes to the availability of puberty blockers for under-18s
GOV.UK
Summarizes Cass Review conclusion of weak evidence for puberty suppression
-
Guideline
Management of gender dysphoria in adolescents in primary care
CMAJ
Canadian primary-care guidance on assessment and hormone timing
-
Guideline
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: Clinical Practice Guideline
Endocrine Society (PubMed)
US guideline recommending staged, multidisciplinary approach starting around age 16
✓Reviewed by CH, MD, FRCPC
Reviewed by a specialist physician certified by the Royal College of Physicians and Surgeons of Canada, who has read this answer against the sources listed above and confirmed it reflects them. That is not medical advice about your child. How we review
Answer checked August 15, 2026